SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn
SBIO’s explosive growth signals strong investor appetite for late-stage biotech, while Big Pharma’s $106B M&A spree validates the fund’s strategy of targeting acquisition-prone assets amid patent cliffs.
Understand this faster with AI
Sean Daly2.16K FollowersFollow5ShareSavePlay(11min)CommentsSummaryALPS Medical Breakthroughs ETF targets late-stage clinical trial biotechs primed for outsized performance and M&A.SBIO’s selective criteria focus on U.S.-listed firms with strong cash positions, Phase 2/3 assets, and near-term catalysts, creating a portfolio of high-volatility, high-alpha 'lottery tickets.'SBIO has delivered 111% returns over the past year, outperforming the S&P 500; its holdings have seen notable buyouts and clinical milestones.The holdings of SBIO are positioned at the epicenter of Big Pharma’s urgent hunt for de-risked, late-stage assets amid looming patent cliffs. jittawit.21/iStock via Getty Images Biotech M&A has been scorching hot this year. Big Pharma spent approximately $106 billion on 201 acquisitions in the first half of 2026. If this pace continues, the industry is expected to close more than This article was written bySean Daly2.16K FollowersFollowSean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. He has also written extensively on real estate and economic development, exploring issues as diverse as Chinese urbanization, CMI multilateral currency swap arrangements, energy geopolitics, and Asia's sovereign wealth funds. Global strategy and private equity background. Equity Approach: long/short, event-driven, with a focus on small cap biotech and the emerging markets.Analyst’s Disclosure: I/we have a beneficial long position in the shares of SBIO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.